Océanie · Bourse & Finance · Stockhead

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Publié par Stockhead · Australie il y a 2 h

CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and ... Read More The post Health Check: CSL places…

Lire l'article complet sur Stockhead Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stockhead.com.au)

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

À lire aussi

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

Fulton Hogan revenues and profits rebound after 2025 downturn

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Partager

À lire aussi

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

Fulton Hogan revenues and profits rebound after 2025 downturn